The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

NAABT, Privacy Policy

Your privacy is of great concern to us. We understand and respect your need for privacy when dealing with health issues, particularly addiction treatment. NAABT, Inc. will not collect any identifiable information about you (name, address, telephone number, or e-mail address) unless you voluntarily provide it to us. Any personal information you do submit to us will not be shared with any third party and will only be used as defined on the information submission page. For example, if you submit your identifiable information in order to receive our free resource kit, that information will only be used to fill that order. Your information will not be published or stored on our website.

You are not required to give us any personal information in order to use the website. The only time you are asked for your personal information is in the event you ask us to mail you something and a mailing address is required. You may download and use the site anonymously and confidentially. Our free TreatmentMatch program has an additional privacy policy. See: TreatmentMatch privacy policy uses Javascript and Cookies to provide certain features to its users. In order to ensure the tools we've created to help you with receiving treatment work properly you need to have Javascript and Cookies enabled. Cookies place small bits of information on your hard drive, like username, password, and zip code. This information is also not shared with anyone and this feature can be turned off, in your browser’s security settings, however if disabled, parts of the site will no longer function.

HIPAA: Although not required of us by law, we meet or exceed HIPAA (Health Insurance Portability and Accountability Act of 1996, Public Law 104-191) standards of privacy in how we store and process the information you voluntarily provide to us. Your connection on pages that contain user-submitted forms with are encrypted with 128bit encryption. The connection is encrypted using RC4_128 with MD5 for message authentication and RSA as the key exchange mechanism. See more about your health information privacy rights at:


This page was last modified on : 10/29/2013

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release